Context

Earlier studies have presented the outcomes of the Women's Health Initiative (WHI), which enrolled women aged 50–79 years and included a trial of conjugated equine oestrogens (CEE) plus medroxyprogesterone acetate (MPA), and a CEE-alone trial.^1,2 Most participants stopped hormone therapy at the end for the formal trial with less than 4% continuing therapy. Most of the data reflects a median of 5.6 years of exposure for CEE+MPA and 7.2 years of exposure for CEE. This report summarises the previous WHI reports alongside 13 years of follow-up in 81.1% of surviving participants. Some selection bias may have occurred in the postintervention phase due to occurrences in the intervention phase.